May 29, 2020
Ipsen Appoints David Loew as Chief Executive Officer
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Board of Directors has appointed David Loew as…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: ipsen
May 23, 2020
Ipsen surveys give insight into the real-life burden of spasticity or cervical dystonia
Ipsen’s results reveal the need for longer-lasting symptoms control to improve patients’ perceived quality of life
April 22, 2020
Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact
Ipsen has continued momentum with Q1 2020 Group sales growth of 9.6% as reported, or 8.7% at constant exchange rates, while 2020 Guidance remains suspended as announced in March given the uncertainty around the duration and scale of the COVID-19 pandemic.
October 24, 2019
Ipsen Delivers Strong Double-digit Sales Growth for the Third Quarter of 2019 and Confirms Full Year 2019 Guidance
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter…
October 16, 2019
Ipsen, Blueprint Medicines in licence deal for BLU-782 for the treatment of Fibrodysplasia Ossificans progressiva (FOP)
Ipsen and Blueprint medicines have entered a deal which expands Ipsen’s rare diseases portfolio to include BLU-782, a highly selective…
September 27, 2019
Ipsen gets FDA approval of Dysport for treatment of Upper Limb Spasticity in children, excluding cerebral palsy
Ipsen got approval for Dysport, the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity, as the pivotal Phase 3 study showed Dysport improved spasticity symptoms in children aged two to 17 experiencing upper limb spasticity, as measured by the primary efficacy endpoint of Modified Ashworth Scale at elbow or wrist flexors at Week 6.
September 26, 2019
Ipsen Showcases Studies at the ESMO 2019 Congress Highlighting Progress in New Approaches for Difficult-to-Treat Cancers
Ipsen’s presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors.
September 23, 2019
Ipsen’s study of Dysport shows improving outcomes of patients living with spastic paresis
Ipsen’s study of Dysport treatment of patients with personalized diary-based rehabilitation program improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.
September 8, 2019
Ipsen and Servier Phase II/III testing Onivyde for small cell lung cancer (SCLC) shows further research is warranted
– 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary…
July 25, 2019
Ipsen delivers strong results for the first half of 2019, Consolidated net profit up 11.8%
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first…